Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 open-label long-term study of PTC923 in phenylketonuria
NL-OMON59101Phase 3Completed
- Sponsor
- PTC Therapeutics, Inc.
- Start
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of sepiapterin in phenylketonuria (PKU), sponsored by PTC Therapeutics, Inc. Primary endpoints: Long-term safety of PTC923 and Change from baseline in dietary phenylalanine/protein consumption. Started Sep 2023; status: completed.
02
Drugs
sepiapterin
03
Conditions
phenylketonuria (PKU)
Beyond the preview
Go deeper on NL-OMON59101.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59101.